Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study

10.1186/s40545-015-0046-2

Saved in:

Bibliographic Details
Main Authors:	Vitry, A, Nguyen, T, Entwistle, V, Roughead, E
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Published:	2020
Subjects:	anthracycline bevacizumab capecitabine docetaxel gemcitabine monoclonal antibody paclitaxel taxane derivative vasculotropin advanced cancer arterial thromboembolism Article bleeding breast cancer cancer survivor controlled study cost effectiveness analysis digestive system perforation drug approval drug efficacy drug marketing drug safety drug withdrawal febrile neutropenia fistula funding glioblastoma health care policy health practitioner human hypertension kidney carcinoma left ventricular systolic dysfunction medical literature metastatic colorectal cancer non small cell lung cancer overall survival posterior reversible encephalopathy syndrome progression free survival proteinuria public health risk management sensory neuropathy venous thromboembolism wound dehiscence
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180354
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-180354
record_format	dspace
spelling	sg-nus-scholar.10635-1803542024-11-12T05:34:23Z Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study Vitry, A Nguyen, T Entwistle, V Roughead, E DEAN'S OFFICE (MEDICINE) anthracycline bevacizumab capecitabine docetaxel gemcitabine monoclonal antibody paclitaxel taxane derivative vasculotropin advanced cancer arterial thromboembolism Article bleeding breast cancer cancer survivor controlled study cost effectiveness analysis digestive system perforation drug approval drug efficacy drug marketing drug safety drug withdrawal febrile neutropenia fistula funding glioblastoma health care policy health practitioner human hypertension kidney carcinoma left ventricular systolic dysfunction medical literature metastatic colorectal cancer non small cell lung cancer overall survival posterior reversible encephalopathy syndrome progression free survival proteinuria public health risk management sensory neuropathy venous thromboembolism wound dehiscence 10.1186/s40545-015-0046-2 Journal of Pharmaceutical Policy and Practice 8 1 1-11 2020-10-26T08:31:49Z 2020-10-26T08:31:49Z 2015 Article Vitry, A, Nguyen, T, Entwistle, V, Roughead, E (2015). Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study. Journal of Pharmaceutical Policy and Practice 8 (1) : 1-11. ScholarBank@NUS Repository. https://doi.org/10.1186/s40545-015-0046-2 20523211 https://scholarbank.nus.edu.sg/handle/10635/180354 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	anthracycline bevacizumab capecitabine docetaxel gemcitabine monoclonal antibody paclitaxel taxane derivative vasculotropin advanced cancer arterial thromboembolism Article bleeding breast cancer cancer survivor controlled study cost effectiveness analysis digestive system perforation drug approval drug efficacy drug marketing drug safety drug withdrawal febrile neutropenia fistula funding glioblastoma health care policy health practitioner human hypertension kidney carcinoma left ventricular systolic dysfunction medical literature metastatic colorectal cancer non small cell lung cancer overall survival posterior reversible encephalopathy syndrome progression free survival proteinuria public health risk management sensory neuropathy venous thromboembolism wound dehiscence
spellingShingle	anthracycline bevacizumab capecitabine docetaxel gemcitabine monoclonal antibody paclitaxel taxane derivative vasculotropin advanced cancer arterial thromboembolism Article bleeding breast cancer cancer survivor controlled study cost effectiveness analysis digestive system perforation drug approval drug efficacy drug marketing drug safety drug withdrawal febrile neutropenia fistula funding glioblastoma health care policy health practitioner human hypertension kidney carcinoma left ventricular systolic dysfunction medical literature metastatic colorectal cancer non small cell lung cancer overall survival posterior reversible encephalopathy syndrome progression free survival proteinuria public health risk management sensory neuropathy venous thromboembolism wound dehiscence Vitry, A Nguyen, T Entwistle, V Roughead, E Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
description	10.1186/s40545-015-0046-2
author2	DEAN'S OFFICE (MEDICINE)
author_facet	DEAN'S OFFICE (MEDICINE) Vitry, A Nguyen, T Entwistle, V Roughead, E
format	Article
author	Vitry, A Nguyen, T Entwistle, V Roughead, E
author_sort	Vitry, A
title	Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
title_short	Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
title_full	Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
title_fullStr	Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
title_full_unstemmed	Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study
title_sort	regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/180354
_version_	1821186577013932032

Regulatory withdrawal of medicines marketed with uncertain benefits: The bevacizumab case study

Similar Items